報價延遲最少15分鐘:2026/04/21 20:26 EDT
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
6.97 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-34.67/-0.48
|
|
企業價值
298.16M
|
| 資產負債 |
|
每股賬面淨值
-3.25
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比較之報價最少15分鐘延遲 (夜盤時段除外)
|
業務概覽
|
|||
| Minerva Neurosciences Inc a clinical-stage biopharmaceutical company focused on the development and commercialization of certain proprietary product candidates to treat patients suffering from central nervous system (CNS) diseases. Its product candidate, Roluperidone, is in development for the treatment of negative symptoms in patients diagnosed with schizophrenia. Its Clinical-Stage Programs include Roluperidone and Seltorexant. The company's operations are organized into one operating and reportable segment focused on the development and commercialization of proprietary product candidates to treat patients suffering from CNS diseases. |
